FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140183817> ?p ?o ?g. }

• W2140183817 endingPage "52" @default.
• W2140183817 startingPage "45" @default.
• W2140183817 abstract "Background and Purpose We wanted to evaluate the efficacy, defined as 2-year disease-free survival (DFS), and safety of bevacizumab/chemoradiation in preoperative and adjuvant settings for patients with stage II/III rectal cancer. Patients and Methods Eligible patients had stage II/III rectal adenocarcinoma, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function, and received preoperative (cohort A) or adjuvant (cohort B) treatment at physician discretion. Patients received 5-fluorouracil (5-FU) as an intravenous infusion (IVCI) 225 mg/m2/d on days 1-42, bevacizumab 5 mg/kg intravenously (I.V.) on days 1 and 15 (cohort A), or every 2 weeks (cohort B), with radiation therapy to 50.4 Gy. After surgery (cohort A) or chemoradiation (cohort B), FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin) and bevacizumab were administered for 4 months and then bevacizumab was given alone for up to 1 year. Results Sixty-six patients (cohort A = 35; cohort B = 31) were enrolled from August 2006-April 2009: median age was 57 years; male patients, 62%; ECOG PS 0, 75%; stage II/III, 31%/69%. In cohort A, the complete pathologic response (pCR) rate was 29% (11% microscopic residual disease, 49% gross disease). Four patients did not undergo surgery (toxicity, 2 patients; progressive disease, 1 patient; patient decision, 1 patient). One- and 2-year DFS for cohorts A/B were 85%/not reached and 97%/89%, respectively (median survival not reached for either cohort). Frequent grade 3/4 toxicity included diarrhea (A cohort, 14%; B cohort, 29%), neutropenia (A cohort, 14%, B cohort, 23%), mucositis (A cohort, 23%, B cohort, 0%), and fatigue (A cohort, 6%, B cohort, 10%). Other serious toxicity included bowel perforation and pelvic infection (cohort A, 1 patient each), bowel perforation (2 patients), anal wound dehiscence (1 patient), perianal infection (2 patients), and rectovaginal fistula (1 patient) (cohort B), without treatment-related death in either cohort. Conclusions Bevacizumab can be added to standard preoperative and adjuvant chemoradiation in most patients with expected and manageable toxicity and may increase treatment efficacy." @default.
• W2140183817 created "2016-06-24" @default.
• W2140183817 creator A5004557221 @default.
• W2140183817 creator A5018054038 @default.
• W2140183817 creator A5028472820 @default.
• W2140183817 creator A5028976895 @default.
• W2140183817 creator A5045139636 @default.
• W2140183817 creator A5065917441 @default.
• W2140183817 creator A5072308451 @default.
• W2140183817 creator A5073724595 @default.
• W2140183817 creator A5079398298 @default.
• W2140183817 creator A5087929151 @default.
• W2140183817 date "2012-03-01" @default.
• W2140183817 modified "2023-10-02" @default.
• W2140183817 title "Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer" @default.
• W2140183817 cites W1994615279 @default.
• W2140183817 cites W2078782778 @default.
• W2140183817 cites W2101995865 @default.
• W2140183817 cites W2108051921 @default.
• W2140183817 cites W2109134893 @default.
• W2140183817 cites W2112768035 @default.
• W2140183817 cites W2113353705 @default.
• W2140183817 cites W2117713501 @default.
• W2140183817 cites W2123669280 @default.
• W2140183817 cites W2124886112 @default.
• W2140183817 cites W2125452425 @default.
• W2140183817 cites W2142167347 @default.
• W2140183817 cites W2145835533 @default.
• W2140183817 cites W2149347983 @default.
• W2140183817 cites W2157769714 @default.
• W2140183817 cites W2160476851 @default.
• W2140183817 cites W2169222051 @default.
• W2140183817 doi "https://doi.org/10.1016/j.clcc.2011.04.002" @default.
• W2140183817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21840771" @default.
• W2140183817 hasPublicationYear "2012" @default.
• W2140183817 type Work @default.
• W2140183817 sameAs 2140183817 @default.
• W2140183817 citedByCount "49" @default.
• W2140183817 countsByYear W21401838172012 @default.
• W2140183817 countsByYear W21401838172013 @default.
• W2140183817 countsByYear W21401838172014 @default.
• W2140183817 countsByYear W21401838172015 @default.
• W2140183817 countsByYear W21401838172016 @default.
• W2140183817 countsByYear W21401838172017 @default.
• W2140183817 countsByYear W21401838172018 @default.
• W2140183817 countsByYear W21401838172019 @default.
• W2140183817 countsByYear W21401838172020 @default.
• W2140183817 countsByYear W21401838172021 @default.
• W2140183817 countsByYear W21401838172022 @default.
• W2140183817 countsByYear W21401838172023 @default.
• W2140183817 crossrefType "journal-article" @default.
• W2140183817 hasAuthorship W2140183817A5004557221 @default.
• W2140183817 hasAuthorship W2140183817A5018054038 @default.
• W2140183817 hasAuthorship W2140183817A5028472820 @default.
• W2140183817 hasAuthorship W2140183817A5028976895 @default.
• W2140183817 hasAuthorship W2140183817A5045139636 @default.
• W2140183817 hasAuthorship W2140183817A5065917441 @default.
• W2140183817 hasAuthorship W2140183817A5072308451 @default.
• W2140183817 hasAuthorship W2140183817A5073724595 @default.
• W2140183817 hasAuthorship W2140183817A5079398298 @default.
• W2140183817 hasAuthorship W2140183817A5087929151 @default.
• W2140183817 hasConcept C121608353 @default.
• W2140183817 hasConcept C126322002 @default.
• W2140183817 hasConcept C141071460 @default.
• W2140183817 hasConcept C2776694085 @default.
• W2140183817 hasConcept C2777802072 @default.
• W2140183817 hasConcept C2780962732 @default.
• W2140183817 hasConcept C526805850 @default.
• W2140183817 hasConcept C71924100 @default.
• W2140183817 hasConcept C72563966 @default.
• W2140183817 hasConcept C90924648 @default.
• W2140183817 hasConceptScore W2140183817C121608353 @default.
• W2140183817 hasConceptScore W2140183817C126322002 @default.
• W2140183817 hasConceptScore W2140183817C141071460 @default.
• W2140183817 hasConceptScore W2140183817C2776694085 @default.
• W2140183817 hasConceptScore W2140183817C2777802072 @default.
• W2140183817 hasConceptScore W2140183817C2780962732 @default.
• W2140183817 hasConceptScore W2140183817C526805850 @default.
• W2140183817 hasConceptScore W2140183817C71924100 @default.
• W2140183817 hasConceptScore W2140183817C72563966 @default.
• W2140183817 hasConceptScore W2140183817C90924648 @default.
• W2140183817 hasIssue "1" @default.
• W2140183817 hasLocation W21401838171 @default.
• W2140183817 hasLocation W21401838172 @default.
• W2140183817 hasOpenAccess W2140183817 @default.
• W2140183817 hasPrimaryLocation W21401838171 @default.
• W2140183817 hasRelatedWork W2003080165 @default.
• W2140183817 hasRelatedWork W2089177637 @default.
• W2140183817 hasRelatedWork W2098707609 @default.
• W2140183817 hasRelatedWork W2145753255 @default.
• W2140183817 hasRelatedWork W2501488762 @default.
• W2140183817 hasRelatedWork W2525270347 @default.
• W2140183817 hasRelatedWork W2602417212 @default.
• W2140183817 hasRelatedWork W3106356697 @default.
• W2140183817 hasRelatedWork W4361823821 @default.
• W2140183817 hasRelatedWork W4384520861 @default.
• W2140183817 hasVolume "11" @default.
• W2140183817 isParatext "false" @default.

• next